Early detection of FXS with methylation specific-quantitative melt analysis (MS-QMA) that targets CpG sites within the FMR1 intron 1 obtained from DNA in newborn blood has immediate applications in FXS diagnostics, with the potential to be used in nationwide newborn screening. This evidence concerns the gene FMR1 and fragile X syndrome.